We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Lists Drug Safety, Transparency as Priorities in Five-Year Plan
FDA Lists Drug Safety, Transparency as Priorities in Five-Year Plan
September 30, 2010
The FDA plans to continue its recent focus on drug safety and transparency over the next five years, with postmarket surveillance and science-based decision making also identified as important areas for the agency, according to a plan released Thursday.